Acadia slims Nuplazid label expansion bid in hopes of clinching Alzheimer's dementia nod without extra studies

Acadia plans to resubmit its application for Nuplazid, also known as pimavanserin, to treat hallucinations and delusions associated with dementia, homing in specifically on patients with Alzheimer’s disease psychosis (ADP), the company said early this week. The San Diego-based company is targeting the first quarter of 2022 for its resubmission.